The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia
Open accessAbstract
More information is needed about genetic factors that initiate development of pancreatic intraepithelial neoplasms-the most common precursors of pancreatic ductal adenocarcinoma. We show that more than 99% of the earliest-stage, lowest-grade, pancreatic intraepithelial neoplasm-1 lesions contain mutations in KRAS, p16/CDKN2A, GNAS, or BRAF. These findings could improve our understanding of the development and progression of these premalignant lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, may be acquired as later events during systemic treatment for metastatic disease and have been found as subclonal genetic alterations in a subset of CRC patients ([25-27])”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, KRAS mutations are often a founder genetic event involved in the pathogenesis of PDAC and are consistently found in precancerous pancreatic intraepithelial neoplasms”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [26]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations are observed in most low-grade PanINs and IPMNs, suggesting KRAS is the initiating genetic event driving exocrine neoplasia46,47.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationCirculating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Self-citationVincent, A., Herman, J. M., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,678
Self-citationPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Self-citationHruban, R. H., Adsay, N. V., Albores–Saavedra, J., Compton, C., Garrett, E. S., Goodman, S. N., Kern, S. E., Klimstra, D. S., Klöppel, G., Longnecker, D. S., et al. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200105000-00003 · Cited by 1,126
Self-citationSenescence-messaging secretome: SMS-ing cellular stress
Kuilman, T., & Peeper, D. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2560 · Cited by 909
Progression model for pancreatic cancer.
Hruban, R. H., Goggins, M., Parsons, J., & Kern, S. E. (2000) · PubMed · Cited by 872
Self-citationRecurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development
Wu, J., Matthaei, H., Maitra, A., Molin, M. D., Wood, L., Eshleman, J., Goggins, M., Canto, M., Schulick, R., Edil, B., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002543 · Cited by 786
Self-citationWhen cells get stressed: an integrative view of cellular senescence
Ben-Porath, I., & Weinberg, R. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420663 · Cited by 404
Flagged first, then by citations
1 of the 22 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Hruban, 2000, Clin Cancer Res, 6, 2969
- Wu, 2011, Sci Transl Med, 3
- Caldwell, 2011, Oncogene
- Wu, 2011, Sci Transl Med, 3
Cited by
Sorted by citations
Items 701–743 of 743
Xie, C., Ke, J., & Liu, F. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.12.008 · Cited by 1
Mai, T., Wang, M., Qiu, Y., Lu, W., Wu, H., Chen, S., Chiao, P. J., & Huang, P. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.111057 · Cited by 1
ADAM17-dependent Autocrine and Paracrine Signaling Promotes Pancreatic Premalignant Progression
Wen, H.-J., Davis, E. T., Moore, J. S., Brender, S. M., Benitz, S., Wombwell, A. M., Loveless, I. M., Long, D. W., Salas-Escabillas, D. J., Lee, J., et al. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101711
Han, W., Shi, D., Yang, Q., Li, X., Zhang, J., Peng, C., & Yan, F. (2024) · Figshare · doi:10.6084/m9.figshare.25282916
Han, W., Shi, D., Yang, Q., Li, X., Zhang, J., Peng, C., & Yan, F. (2024) · Figshare · doi:10.6084/m9.figshare.25282771
From bench to bedside: pancreatic juice as a platform for biomarker discovery in pancreatic disease
Siddappa, P. K., Kong, N., Lee, A. A., Jiang, Y., & Park, W. G. (2026) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.216
PPARδ: An underappreciated tumor accelerator in pancreatic ductal adenocarcinoma
Niu, D., Wei, D., Liu, Y., Yao, J. C., Shureiqi, I., & Zuo, X. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218385
Marin, A. M., Timoner, B. E., Araújo, D. D., Uno, M., Alves, M. J. F., Chammas, R. J., Namur, G. N., Wosniaki, D. K., Canzian, F., Blanes, L., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-42403-4
Li, Y.-T., Zhang, Y.-P., Fang, Q.-D., Wu, H.-W., Xiao, Y., Wu, W.-M., Xue, H., Jin, Z.-Y., & Wang, Z.-W. (2026) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v18.i3.115320
Etude de la reprogrammation métabolique de l' adénocarcinome canalaire pancréatique
Olivares, O. (2015) · theses.fr (ABES) · doi:10.70675/ef2c6a2czab6dz4a68z8004z1ade8605dadc
Carmona, S. (2017) · theses.fr (ABES) · doi:10.70675/f95cdb23zecb6z4543z9164ze58fd37f2268
Pietrasz, D. (2021) · theses.fr (ABES) · doi:10.70675/c472e16fzf3fdz431dz883cz48ea933497f9
Exploring PI3K signalling dynamics in pancreatic cancer
Delgado, C. F. R. (2020) · theses.fr (ABES) · doi:10.70675/6df9a059zc3f1z4997z9de2z34a1d24dfbeb
Inflammatory memory disables a DDR1 degradation checkpoint to enable pancreatic cancer growthPreprint
Yang, F., Lin, B., Yuan, Z., Yuan, Y., Pu, X., Wang, C., Watari, K., Luo, R., Sun, B., Karin, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.01.715820
Identification of therapeutic targets of nucleolin-related pathways in pancreatic cancer therapy
Raineri, F. (2020) · theses.fr (ABES) · doi:10.70675/b0a30a01z777cz4da7z90cbz3e9a95dd1630
Reyes, J. (2026) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · doi:10.5281/zenodo.18892592
Endo, M., Niisato, Y., Shimomura, O., Sakamoto, N., Sugita, S., Hagiwara, Y., Fukuda, S., Matsubara, D., Oda, T., & Tsuchiya, K. (2026) · International Journal of Surgical Pathology · doi:10.1177/10668969261437128
Haidar, H. (2024) · theses.fr (ABES) · doi:10.70675/3c9a1953zce0cz4a3ez9a7bz7328f996231c
Zhang, L., Xue, F., Cheng, Y., 侯美荣, Wu, S., Ren, J., Ma, Z., Wang, Z., Wu, R., & Wu, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1744027
The role of inflammation in the immune evasion of KRas
Homan, E. J., & Bremel, R. D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1831303 · Cited by 1
Haegele, L. M., Thomsen, A. R., Grosu, A., Fichtner-Feigl, S., Ruess, D. A., & Wittel, U. A. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45038
Madriles, F., de Andrés, M. P., Chesnokov, M., de Villarreal, J. M., Alonso‐Curbelo, D., del Pozo, N., Iglesias, M., Pau, E. C. D. S., Iovanna, J., Soriano, F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.22.724502
Zhang, Y., Kadiyala, P., Yan, W., Brown, K. L., Avritt, F. R., Donahue, K. L., Procario, M. C., Okoye, J. O., Giridharan, T., Elhossiny, A. M., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-1300
Pham, H. T., Bussey, K. J., Oshiro, M. M., Rounseville, M., Moses, M., Zulbaran‐Rojas, A., Nguyen, V. A., Bernert, R. A., Routh, J., Watts, G. S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.27.728292
A human model of progressive pancreatic neoplasia and cancer
Escobar, D., & Crawford, H. C. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.05.005
Genetic polymorphisms of DNA repair pathways in pancreatic cancer progression and treatment
Saraf, F., Purohit, M. R., Lakshmisundaram, R., Verma, H. K., & Bhaskar, L. V. K. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43976-6.00017-x
Yang, X., Tao, X., Qi, W., Luo, R., Lan, T., Xie, K., Cai, Y., Gao, F., Lv, Y., Liu, C., et al. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101718
HAGIWARA, Y., Tamamura, N., Sumida, N., Ono, Y., Takahashi, K., Sun, Y., Koyama, K., Ohtaki, Y., Okada, T., Kawabata, H., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103042
Sato, M., Kitahata, Y., Nakamura, Y., Motobayashi, H., Takemoto, N., Nakai, T., Hyo, T., Ueno, M., Hayami, S., Miyamoto, A., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20286-z · Cited by 1
Hruban, R. H., & Kern, S. E. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101059
Self-citationKawamoto, Y., Honda, G., Kikuyama, M., Takayama, Y., Saito, S., Itoh, T., Furukawa, T., Horiguchi, S., Nakahodo, J., Sagami, R., et al. (2026) · Pancreatology · doi:10.1016/j.pan.2026.08.011
Tezcan, N., Atasoy, D., Saka, B., Armutlu, A., Mericoz, C. A., Esmer, R., Bağcı, P., Pehlivanoğlu, B., Balcı, S., Muraki, T., et al. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04705-w
Inflammatory memory inactivates AMPK-stimulated DDR1 degradation to enable pancreatic cancer growth
Yang, F., Lin, B., Yuan, Y., Yuan, Z., Pu, X., Wang, C., Zhang, D., Yang, Y., Watari, K., Luo, R., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2616901123
Williams, T. M., Moughan, J., Regine, W. F., Timmers, C. D., Robb, R. N., Cui, T., DiPetrillo, T. A., Leasure, N. C., Kim, H., Doncals, D. E., et al. (2026) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2026.09.014
In vitro investigation of the anticancer properties of melatonin and its relationship with sirtuins
YILDIRIM, S., & Özden, Ö. (2026) · Journal of Proteins and Proteomics · doi:10.1007/s42485-026-00220-3
Strategies to develop therapeutic cancer vaccines for pancreatic cancer
Coppi, M. M., Graciotti, M., Digklia, A., & Kandalaft, L. E. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00149-4
Casimiro, P. D. O., Mondragón, M. F. L., Lee, P. P., Morales, J. E. A., & Hill, L. D. D. (2026) · International Journal of Research in Dermatology · doi:10.18203/issn.2455-4529.intjresdermatol20263751
Erreni, M., Fumagalli, M. R., D’Anna, R., Sollai, M., Bozzarelli, S., Nappo, G., Zanini, D., Parente, R., Garlanda, C., Rimassa, L., et al. (2025) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.15005984
Mouse Models of RAS-Induced Tumors and Developmental Disorders
Guerra, C. E., & Barbacid, M. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1806-1_10
Metadata
- Authors
- Kanda, M., Matthaei, H., Wu, J., Hong, S., Yu, J., Borges, M., Hruban, R. H., Maitra, A., Kinzler, K., Vogelstein, B., & Goggins, M.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Goggins, Michael
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 142
- Issue
- 4
- Pages
- 730-733.e9
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC3321090
- OpenAlex
- W2081681778
- Cited by
- 741
- References
- 22
- Citations by year
- 2026: 45 · 2025: 51 · 2024: 47 · 2023: 57 · 2022: 47 · 2021: 76 · 2020: 49 · 2019: 41 · 2018: 61 · 2017: 68 · 2016: 50 · 2015: 44 · 2014: 39 · 2013: 40 · 2012: 25
- FWCI
- 23.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Krebshilfe
- Lustgarten Foundation
- National Institutes of Health (CA62924, R01CA120432, P01CA134292, R01CA97075, RC2CA148376)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic intraepithelial neoplasia, somatic mutations, KRAS, CDKN2A, p16, GNAS, BRAF, pancreatic ductal adenocarcinoma, precancerous lesions, tumor progression, genetic susceptibility
- MeSH terms
- Carcinoma in Situ, Chromogranins, DNA Mutational Analysis, Humans, Mutation, Neoplasm Staging, Pancreatic Neoplasms, Phenotype, Proto-Oncogene Proteins, Baltimore, Proto-Oncogene Proteins p21(ras), ras Proteins, GTP-Binding Protein alpha Subunits, Gs, Cyclin-Dependent Kinase Inhibitor p16, Genetic Predisposition to Disease, Carcinoma, Pancreatic Ductal, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
